<DOC>
	<DOCNO>NCT02557269</DOCNO>
	<brief_summary>ASIT naïve patient sensitized grass pollen recruit study . All instructed treat bothersome in-season symptom appear ( need , pro nata basis ) rescue medication . They give 5 different option inform effect order make optimal choice different symptom combination : local decongestant ( xylomethazoline , congestion lead ) , local antihistamine ( azelastine , itch , sneeze rhinorhea predominant ) , nasal corticosteroid ( momethasone , nasal symptom press adequate relief obtain form 2 local treatment ) , oral antihistamine ( bilastine , itch sneeze persist despite local treatment ) oral corticosteroid ( prednisolone , symptoms become unbearable despite suggested treatment ) . Patients reluctant use immunotherapy late initiate randomize treat listed medication need basis , nasally apply formulation follow either HPMC prolong enhance effect ( Group HPMC ) placebo ( lactose powder ) ( Group Placebo ) serve control . Patients indicate willing carry ASIT treat accord standard protocol grass allergens sublingually ( Staloral # 688 ) receive rescue medication ( Group Immunotherapy ) .</brief_summary>
	<brief_title>4 '' S '' - Seasonal Symptoms Suppression Study</brief_title>
	<detailed_description>Rationale . Assessment follow specifically sensitize subject allergic rhinitis pollen season traditionally base symptom score . Accounting use rescue medication top symptom score provide another dimension overall clinical characterization patient . Thus , use `` combine symptom medication score '' ( CSMS ) allow thorough characterization disease course . Guidelines recommend CSMS use assessment effect allergen specific immunotherapy subject allergic rhinitis . Different allergic rhinitis management strategy evaluate compare mean CSMS . In update ARIA guideline 2010 , 24 recommendation make relation pharmacologic treatment . Special position paper devote severe chronic upper airway disease ( SCUAD ) , treatment earmark unmet need . Consequently , standardize universally recognize rescue treatment strategy exist . The common approach handle nasal complaint real life consist use rescue medication symptom whenever appear . This certainly case symptom appear first time ever , patient want resort allergen specific immunotherapy ( ASIT ) / regular oral antihistamine treatment financial reason personal belief . Under circumstance , long list pharmacological choice local systemic application possible include antihistamine , corticosteroid , leukotriene antagonist , cromones antimuscarinic drug . Formulations local application nose appeal patient ease use immediate relief . They comprise variety generic drug : decongestant , antihistamine , corticosteroid antimuscarinics . The fact ingest make first choice people reluctant take oral medication . In many case possible control symptoms allergic rhinitis formulation use per se adjunct rescue medication course ASIT . The question stay whether effectiveness nasally apply drug improve . Despite good rationale mechanism action , efficacy diminish clean mechanism nose , rhinorrhea particular . Slowing clearance nasal mucosa prolong contact time nasal mucosa would enhance pharmaceutical effect . The investigator demonstrate objectively measure nasal flow rate `` seal '' place locally apply oxymetazoline subject persistent allergic rhinitis mean commercially available hydroxyl-propyl-methyl-cellulose ( HPMC ) significantly enhance result decongestion effect augment time span 2 week without noticeable tachyphylaxis adverse event . The investigator set aim investigate whether beneficial effect HPMC translate clinical benefit real life clinical trial available drug preparation nasal delivery . Study design . ASIT naïve patient sensitized grass pollen recruit study . All patient instruct treat bothersome in-season symptom appear ( need , pro nata basis ) rescue medication . The patient give 5 different option inform effect order make optimal choice different symptom combination : local decongestant ( xylomethazoline , congestion lead ) , local antihistamine ( azelastine , itch , sneeze rhinorhea predominant ) , nasal corticosteroid ( momethasone , nasal symptom press adequate relief obtain form 2 local treatment ) , oral antihistamine ( bilastine , itch sneeze persist despite local treatment ) oral corticosteroid ( prednisolone , symptoms become unbearable despite suggested treatment ) . Patients reluctant use immunotherapy late initiate randomize treat listed medication need basis , nasally apply formulation follow either HPMC prolong enhance effect ( Group HPMC ) placebo ( lactose powder ) ( Group Placebo ) serve control . Patients indicate willing carry ASIT treat accord standard protocol grass allergens sublingually ( Staloral # 688 ) receive rescue medication ( Group Immunotherapy ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<mesh_term>Xylometazoline</mesh_term>
	<criteria>Male female patient Age ≥ 18 ≤ 55 year Personal history rhinitis pollen season Moderately severe / severe seasonal allergic rhinitis ( grass ) Positive skin prick test grass/cereals Subjects arterial hypertension , arrhythmia evidence heart ischemia Subjects serious chronic comorbidities bad therapeutic control Subjects nasal polyposis Any contraindication xylometazoline Any contraindication HPMC Any contraindication azelastine Any contraindication bilastine Any contraindication mometasone Any contraindication prednisolone Subjects unable give inform consent Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pollenosis</keyword>
	<keyword>Congestion</keyword>
	<keyword>Mucoadhesive Treatment</keyword>
	<keyword>Nasal Decongestant</keyword>
	<keyword>Nasal Antihistamine</keyword>
	<keyword>Nasal Corticosteroid</keyword>
</DOC>